• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Oncology

Rucaparib compared to standard-of-care chemotherapy showed promising clinical and safe response to treat BRCA1 or BRCA2 mutated, relapsed ovarian carcinoma

byJamie ParkandSze Wah Samuel Chan
March 21, 2022
in Oncology
Reading Time: 3 mins read
Quick Take: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
Share on FacebookShare on TwitterShare on LinkedIn

1. The median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in the chemotherapy group for both the intention-to-treat and efficacy-evaluable group.

2. Common treatment-related adverse events in patients receiving rucaparib were anemia, nausea, fatigue.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Rucaparib is an oral poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor approved to treat BRCA1- or BRCA2-mutated relapsed ovarian carcinoma in certain countries. However, there is limited knowledge on the efficacy and safety data of rucaparib compared with non-platinum-based chemotherapies. Therefore, this study aimed to explore the efficacy and safety of rucaparib compared to both platinum and non-platinum-based chemotherapies in patients with BRCA1– or BRCA2-mutated, relapsed ovarian carcinoma, who have previously received two or more chemotherapy regimens. For both the intention-to-treat and efficacy-evaluable group, the median progression-free survival was 7.4 months in the rucaparib group and 5.7 months in the chemotherapy group. The efficacy group was defined as all randomly assigned patients with BRCA1 and BRCA2 mutations with no reversion mutations. Anemia/decreased hemoglobin, nausea and/or asthenia/fatigue were common treatment-related adverse events that were reported. The main limitation of the analyses included limited data for diverse ethnicities. The majority of the study population was White. Overall, this study demonstrated continual support that rucaparib can be used to treat BRCA1– or BRCA2-mutated, relapsed ovarian carcinoma. However, further investigation is required to examine the long-term efficacy and safety profile of rucaparib.

Click to read the study in The Lancet

Relevant Reading: Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

RELATED REPORTS

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

Earlier genetic testing predicts bilateral mastectomy in young BRCA carriers

In-Depth [randomized controlled trial]: This was an international, open-label, randomized, phase III study. Patients were enrolled if they had BRCA1– or BRCA2-mutated ovarian carcinoma and previously received at least two or more chemotherapy regimens A total of 349 patients were enrolled to receive either study treatment (n=233) or platinum-based/non-platinum-based chemotherapy (n=116). The demographic of both rucaparib and chemotherapy groups were well-balanced. The median follow-up period was 25.0 months (interquartile range [IQR]: 52-64). The median progression-free survival for the intention-to-treat population was 7.4 months (95% confidence interval [CI]: 6.7-7.9) in the rucaparib group and 5.7 months in the chemotherapy group (95% CI: 5.5-6.7). The hazard ratio [HR] was 0.67 [95% CI: 0.52-0.86; p=0.0017]. In the efficacy population, the median progression-free survival for the rucaparib group was 7.4 months (95% confidence interval [CI]: 7.3-9.1) and 5.7 months in the chemotherapy group (95% CI: 5.5-7.3). The hazard ratio [HR] was 0.64 [95% CI: 0.49-0.84; p=0.0017]. Most of the patients experienced grade 1/2 treatment-related adverse events. Common treatment-related adverse events of any grade included anemia/decreased hemoglobin (31%), nausea (51%) and/or asthenia/fatigue (41%). 27% of the patients in the rucaparib group versus 12% in the chemotherapy group experienced serious treatment-related adverse events.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: BRCA mutationovarian cancerrucaparib
Previous Post

Valoctocogene roxaparvovec gene therapy efficacious for hemophilia A treatment

Next Post

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

RelatedReports

A collage illustrating the urinary bladder, immune system elements, cancer cells, and an IV bag, highlighting immunotherapy for urothelial cancer.
Chronic Disease

The use of neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer may reduce mortality

September 22, 2026
Breast cancer collage: a white peony, a cheek swab beside its open tube and a small dish holding two capsules
Surgery

Earlier genetic testing predicts bilateral mastectomy in young BRCA carriers

September 11, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Chronic Disease

Early menarche and later menopause are associated with increased ovarian cancer risk

February 13, 2026
Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial
Weekly Rewinds

2 Minute Medicine Rewind February 9, 2026

February 9, 2026
Next Post
Multidrug induction therapy increases remission from lupus nephritis

Iberdomide elicits SRI-4 response in patients with systemic lupus erythematosus

Preoperative bilateral breast imaging may reduce contralateral cancer recurrence

Ribociclib in addition to letrozole increases overall survival compared to letrozole alone

Pembrolizumab as a promising treatment in patients with classic or endemic Kaposi’s sarcoma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.